PMID: 7031187Sep 1, 1981Paper

Metoprolol and propranolol in essential tremor: a double-blind, controlled study

Journal of Neurology, Neurosurgery, and Psychiatry
S CalzettiA Richens

Abstract

Single oral doses of propranolol (120 mg), metoprolol (150 mg) and placebo were given in a randomised, double-blind fashion to 23 patients with essential tremor. Both beta blockers were significantly more effective than placebo in reducing the magnitude of tremor. The decrease in tremor produced by metoprolol (47, sem 9%, n = 23) was not significantly different from that observed propranolol (55, sem 5%, n = 23). Tachycardia on standing was antagonised by both drugs to a similar extent. These findings suggest that metoprolol may represent a valuable alternative to propranolol in the treatment of essential tremor. The data is consistent with the hypothesis that the tremorolytic effect of beta blockers in these patients may be unrelated to peripheral beta-2 adreno-receptor blockade, being possibly mediated by other central or peripheral modes of action of these drugs. However, it cannot be excluded that at the dose used, metoprolol had lost its relative cardio-selectivity and that the reduction in tremor was mediated by competitive antagonism at beta-2 receptor sites in skeletal muscle.

References

Sep 27, 1979·The New England Journal of Medicine·J Koch-Weser
Aug 9, 1979·The New England Journal of Medicine·C W Britt, B H Peters
Sep 20, 1979·The New England Journal of Medicine·T Riley, A B Pleet
Nov 1, 1979·The New England Journal of Medicine·O Ljung
Oct 1, 1979·Journal of Neurology, Neurosurgery, and Psychiatry·D JeffersonC D Marsden
Jan 1, 1975·Acta Pharmacologica Et Toxicologica·G JohnssonL Sölvell
Jan 1, 1976·Neurology·H TeräväinenA Larsen
Jul 12, 1975·The Medical Journal of Australia·J M SutherlandM J Eadie
Mar 1, 1975·Neurology·J H GrowdonR R Young
Nov 6, 1975·The New England Journal of Medicine·R R YoungB T Shahani
Nov 1, 1975·Neurology·E S Tolosa, R B Loewenson
Aug 1, 1973·Journal of Neurology, Neurosurgery, and Psychiatry·M H MorganR Cooper
May 2, 1974·The New England Journal of Medicine·G F Winkler, R R Young
Jan 12, 1980·Lancet·D M Turnbull, D A Shaw
Feb 23, 1980·Lancet·D Jefferson, C D Marsden
May 10, 1980·Lancet·O Ljung
Sep 1, 1980·Archives of Neurology·R P Newman, L Jacobs
Jun 1, 1949·Brain : a Journal of Neurology·M CRITCHLEY
Feb 1, 1974·British Journal of Clinical Pharmacology·J M EkueM J Walsh
Apr 1, 1974·British Journal of Clinical Pharmacology·S G CarruthersR G Shanks

❮ Previous
Next ❯

Citations

Jul 25, 2013·Current Treatment Options in Neurology·Theresa A ZesiewiczKelly L Sullivan
Jan 1, 1990·Pharmacology & Therapeutics·J McAinsh, J M Cruickshank
Dec 15, 1981·American Journal of Obstetrics and Gynecology·H L NadlerA B Gerbie
Nov 28, 1981·Lancet·S CalzettiA Richens
Apr 14, 1984·Lancet·G M Aronoff
Oct 1, 1982·Journal of Neurology, Neurosurgery, and Psychiatry·S CalzettiA Richens
Nov 18, 2010·Drugs·Reza Sadeghi, William G Ondo
Mar 10, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Jack J Chen, Kelly C Lee
Oct 4, 2003·Pharmacotherapy·Jack J Chen, David M Swope
Dec 1, 1987·British Journal of Clinical Pharmacology·D JeffersonJ M Patrick
Jul 1, 1986·Acta Neurologica Scandinavica·H TeräväinenT A Larsen
Sep 1, 1984·British Journal of Clinical Pharmacology·H J WharradJ M Roland
Aug 2, 2003·The American Journal of Medicine·Rajesh Pahwa, Kelly E Lyons
Sep 1, 1991·Cephalalgia : an International Journal of Headache·M Banerjee, L Findley
Jan 5, 2014·Journal of Central Nervous System Disease·Peter HederaThomas L Davis
Aug 28, 1982·British Medical Journal·R A Harrad, P G Kennedy
May 9, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kelly E LyonsRay L Watts
Oct 3, 2019·Postgraduate Medical Journal·Soumya Sharma, Sanjay Pandey
Jan 25, 2020·Current Neuropharmacology·Hortensia Alonso-NavarroFélix J Jiménez-Jiménez
Sep 12, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Franziska Hopfner, Günther Deuschl
Nov 1, 1982·Acta Neurologica Scandinavica·T A LarsenD B Calne
Sep 1, 2004·The Neurologist·Kelly L SullivanTheresa A Zesiewicz
Aug 28, 1982·British Medical Journal·L J Findley, S Calzetti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
R R YoungB T Shahani
Journal of Neurology, Neurosurgery, and Psychiatry
S CalzettiA Richens
Movement Disorders : Official Journal of the Movement Disorder Society
W C KollerS Cone
The New England Journal of Medicine
C W Britt, B H Peters
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
D I GunalS Aktan
© 2021 Meta ULC. All rights reserved